Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... William E. Saxelby , its President and Chief ... Chief Executive Officer and as a member of the ... He will be replaced on an interim basis by ...
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Dec. 29, 2010 Reportlinker.com announces that a new ... Mammography World Markets ... poised for a major new phase of growth fueled ... the computer and digital areas and the higher interest ...
... (Nasdaq: OMER ), a biopharmaceutical company ... on inflammation and disorders of the central nervous ... clinical trial of OMS201, the Company,s urological PharmacoSurgery™ ... an anti-inflammatory agent and a smooth muscle relaxant, ...
Cached Medicine Technology:Reportlinker Adds Mammography World Markets 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 3
(Date:8/22/2014)... August 22, 2014 The New Jersey ... at Rutgers, the State University of New Jersey has ... children’s media organization, to educate young people about health ... on the strengths of both organizations. , The partnership ... health communications fellowship program, and video communications. ChopChop ...
(Date:8/22/2014)... Dennis Thompson ... News) -- The two American health-care workers infected with ... in West Africa have been released from the Atlanta ... weeks, officials said Thursday. Dr. Kent Brantly, 33, ... Nancy Writebol left the hospital Tuesday. Her family said ...
(Date:8/22/2014)... The leather seat covers provided by Lseat.comare meticulously ... customers’specific product needs. Recently, the company has unveiled its latest ... The company wants to provide worldwide clients with more high ... industry for a long time. According to the company’s sales ... rates. Among all the new products, Chevrolet Camaro leather ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Lincolnshire Marriott ... their meetings with a tap, announcing Marriott’s new iPad ... take advantage of this exclusive offer will receive a ... and set up the day’s agenda with ease. Marriott’s ... make on-the-fly changes and connect with their group with ...
(Date:8/22/2014)... 22, 2014 Minorities in Orange and Los ... comes to mental health and recovery from trauma. Casa de ... the gap between local minorities and the help they need. ... by making the connection between mental and physical health. , ... at their fitness boot camp, located at 16560 Harbor Blvd., ...
Breaking Medicine News(10 mins):Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 2Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 3Health News:Custom 1993-1996 Chevrolet Camaro Leather Seat Covers Now for Sale at Lseat.com 2Health News:Lincolnshire Marriott Resort Offers iPad Mini for Chicago Meeting Planners 2Health News:Fountain Valley Fit Body Boot Camp Announces Fitness Boot Camp Fundraising Event for Casa de Familia 2Health News:Fountain Valley Fit Body Boot Camp Announces Fitness Boot Camp Fundraising Event for Casa de Familia 3
... to get the right information about product,risks and ... MEETING, Pa., June 4 ECRI,Institute, (http://www.ecri.org ... approaches to improving patient care, has enhanced its,Alerts ... coverage of healthcare products and new alert filters., ...
... 4 Unilens Vision Inc. (OTC,Bulletin Board: ... manufactures, distributes and markets specialty contact lenses,today ... Unilens GP (Gas Permeable),products., Unilens, known ... Lens,Company", continues its tradition of providing outstanding ...
... MOUNTAINSIDE, N.J., June 4 L&M Healthcare,Communications LLC, ... of a new full-service Midwest office in Milwaukee,Wis. ... President, Client Services., These enhancements allow L&M ... meet the needs of their growing client,portfolio. Todd ...
... WASHINGTON, June 4 As talk of ... sales bring up,worries about the nation,s economic health, ... are stressed and anxious about,their financial future. An ... that,two-thirds (66 percent) of Americans identify the economy ...
... AstraZeneca (NYSE: AZN) today announced that it submitted ... Food and Drug Administration (FDA) for approval of a ... for the long-term maintenance treatment of asthma in pediatric ... currently approved for the long-term maintenance treatment of asthma ...
... in two health surveys carried out a year apart admitted ... latest Journal of Advanced Nursing. , Thirteen per cent admitted ... a further five per cent reported problems in both surveys. ... to report multiple psychological problems and health complaints. , ...
Cached Medicine News:Health News:ECRI Institute's Alert and Recall Management System Expands Effectiveness with New Content and Filters 2Health News:Unilens Vision Announces New Policies Aimed at Increasing Eye Care Professionals Profitability 2Health News:L&M Healthcare Communications LLC Expands With Hiring of New Executive Staff & Opening of Midwest Office 2Health News:Economy and Money Top Causes of Stress for Americans 2Health News:Economy and Money Top Causes of Stress for Americans 3Health News:AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6 2Health News:Nearly 1 in 5 teenagers admit eating problems, but anxiety is a bigger problem than appearance 2
Infusion Cannula, 2.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
Medicine Products: